CLINICAL TRIAL SUMMARY

MDACC Study No:2011-1165 (clinicaltrials.gov NCT No: NCT01590082)
Title:Phase I / II Study of the Combination of Doxycycline with Temozolomide and Ipilimumab in patients with Metastatic Melanoma
Principal Investigator:Sapna P. Patel
Treatment Agent:Doxycycline; Ipilimumab; Temozolomide
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of doxycycline that can be combined with temozolomide and ipilimumab in
patients with advanced melanoma. The safety and level of effectiveness of the
study drug combination will also be studied.

Doxycycline is designed to treat bacterial infection. It also blocks a protein
called iNOS that is important in tumor cell growth, which may slow the growth
of or kill cancer cells.

Temozolomide is designed to stop cancer cells from making new DNA (the genetic
material of cells). This may stop the cancer cells from dividing into new
cells.

Ipilimumab is designed to block the activity of cells that decrease the immune
system's ability to fight cancer.

Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I/Phase II
Treatment Agents:Doxycycline
Ipilimumab
Temozolomide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:National Institute of Health/ National Cancer Institute
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sapna P. Patel
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults